Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subjects’ satisfaction on pan facial aesthetic enhancement after treatment with Azzalure and the Restylane range
2011-004592-36Phase 3Completed
- Sponsor
- Galderma
- Start
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, single-arm trial of botulinum toxin type A and nasha hyaluronic acid in facial volume loss, rhytides and wrinkly skin syndrome (WSS), sponsored by Galderma. Primary endpoint: Subject satisfaction. Started Oct 2011; status: completed.
02
Drugs
botulinum toxin type Anasha hyaluronic acid
03
Conditions
facial volume lossrhytideswrinkly skin syndrome (WSS)
Beyond the preview
Go deeper on 2011-004592-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004592-36.